HCPLive Network

Higher Dose of Fulvestrant Associated With Improved Survival in Advanced Breast Cancer

Postmenopausal women with advanced estrogen receptor–positive breast cancer lived longer when they received a 500-mg dose of fulvestrant as compared with a 250-mg dose.

Click here to view this article.


Further Reading
The leading cause of cancer related deaths in both men and women is lung cancer. The 5-year survival rate of lung cancer is only 16%, as 75% of patients with lung cancer are presented with symptoms of advanced disease.
A new multi-step skin testing protocol effectively determines the presence of isosulfan blue allergy, according to a study conducted by researchers at the University of Virginia.
Using the metric of time to first cigarette after waking was found to help improve efficiency and reduce false-positive detection in lung cancer screening, a new case-control study suggests.
Widely known to prevent signs of aging, injections of Botox (onabotulinumtoxinA) could also be used to sever nerves to halt tumor growth in gastrointestinal cancer
For patients with advanced laryngeal cancer, there is a small but significant survival advantage with surgical treatment versus laryngeal conservation, according to a study published online Aug. 21 in JAMA Otolaryngology-Head & Neck Surgery.
Active surveillance for clinical stage I testis cancer leads to excellent outcomes, according to a study published online Aug. 18 in the Journal of Clinical Oncology.
Just 6% of individuals with pancreatic cancer live 5 years after diagnosis, and almost half of newly diagnosed pancreatic cancer presents as new-onset diabetes mellitus.
More Reading